Floatz logo

Amantadine

Choreatic Disease

Novartis PharmaceuticalsSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Choreatic Disease cohort.

Asset / SponsorPhaseRating
Deutetrabenazine
Teva Branded Pharmaceutical Products R&D LLC
Phase 4BBB
Atomoxetine
University of Iowa
Phase 2B
Risperidone
University of Rochester
Phase 2B
Citalopram
University of Iowa
Phase 2B
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)-
Novartis Pharmaceuticals
Phase 2CCC

Same molecule, other indications

Amantadine is also rated in:

drug-induced dyskinesiaDormant
BBB
Indicative · Phase 3
72 / 100
View asset →
Parkinson diseaseActive
BBB
Indicative · Phase 4
72 / 100
View asset →
traumatic brain injuryActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →